Breaking News

CCBR-SYNARC, BioClinica To Merge

By Kristin Brooks | January 16, 2014

Jeffrey McMullen appointed chairman

CCBR-SYNARC and BioClinica have signed an agreement to merge, creating a global provider of outsourced clinical services from centers throughout Asia, Europe and The Americas. The combined company will offer a portfolio of services for conducting and managing global clinical trials. The transaction is expected to close in 1Q14. Financial terms were not disclosed.
Jeffrey McMullen, vice chairman of inVentiv Health, Inc., will serve as chairman of the combined company. Mark Weinstein, president and chief executive officer of BioClinica, will serve as chief executive officer.
The combined company will offer medical imaging services across multiple therapeutic areas, a worldwide network of research centers dedicated to recruiting patients for global trials, provide technology and consulting services, monitor cardiac safety of compounds, as well as provide central lab services.
Mr. McMullen said, “This is a ground-breaking merger that will bring together two of the industry’s most experienced providers of specialized clinical trial services. Combining CCBR-SYNARC and BioClinica into a single company will offer customers exceptional scientific expertise and sophisticated technologies to support their drug development processes and accelerate the pace of their innovation.”

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.